Biotech Values

[rkrw]

Doctors can already test for mutations. The issue was the FDA wants standardized test for approval. This is what seemingly prevented Chemgenix from getting approved last year. Kind of silly imo to prevent approval based on that but that's what the FDA wants.

Mutations develop after treatment, so it would not allow for Ponatanib to be first line. But it could be second line when patients test positive for this mutation. Bear in mind though that this would be a very small amount of patients.